Table 1.
Comparisons of baseline characteristics at the time of allograft IgAN diagnosis according to anti-hypertensive medication prescription
| No medication | Single RAASB | Single BB/CCB | Combination | |
|---|---|---|---|---|
| (N=272) | (N=38) | (N=33) | (N=121) | |
| Age at allograft IgAN Dx (years) | 44 [34-50] | 41 [36-47] | 44 [32-54] | 43 [35-51] |
| Male Sex | 181 (66.5%) | 22 (57.9%) | 25 (75.8%) | 83 (68.6%) |
| Duration from transplant to allograft IgAN diagnosis (years) | 3.8 [ 0.7- 7.5] | 6.7 [ 3.2- 9.2] | 5.4 [ 2.8- 8.1] | 5.1 [ 2.0- 9.3] |
| Blood pressure (mmHg) | ||||
| Systolic BP | 129.0 [117.0-138.0] | 120.0 [110.0-133.0] | 120.0 [115.0-136.0] | 129.0 [118.5-139.0] |
| Diastolic BP | 78.0 [70.0-86.0] | 74.0 [65.0-80.0] | 78.0 [70.0-85.0] | 80.0 [70.0-88.0] |
| MAP | 94.3 [85.3-101.3] | 84.8 [79.7-92.7] | 93.0 [85.7-100.7] | 94.3 [85.0-101.0] |
| Laboratory values | ||||
| Serum creatinine (mg/dL) | 1.7 [ 1.4- 2.0] | 1.5 [ 1.2- 2.1] | 1.9 [ 1.6- 2.6] | 1.7 [ 1.4- 2.2] |
| eGFR (mL/min/1.73 m2) | 45.0 [35.4-57.0] | 50.9 [36.9-70.3] | 38.0 [27.3-45.9] | 45.1 [33.8-60.5] |
| Albuminuria | ||||
| None or trace | 189 (69.7%) | 9 (23.7%) | 20 (60.6%) | 42 (35.0%) |
| 1+ | 27 (10.0%) | 8 (21.1%) | 7 (21.2%) | 17 (14.2%) |
| =2+ | 55 (20.3%) | 21 (55.3%) | 6 (18.2%) | 61 (50.8%) |
| Hematuria | 18 (6.6%) | 18 (47.4%) | 6 (18.2%) | 41 (33.9%) |
| Other medication usage | ||||
| Tacrolimus | 138 (50.7) | 16 (42.1) | 20 (60.6) | 51 (42.1) |
| Steroid | 257 (94.5) | 35 (92.1) | 31 (93.9) | 112 (92.6) |
| Mycophenolic acid | 182 (66.9) | 30 (78.9) | 24 (72.7) | 94 (77.7) |
| Donor characteristics | ||||
| Age | 39 [31-47] | 36 [30-42] | 40 [28-47] | 40 [30-48] |
| Male sex | 151 (55.5%) | 21 (55.3%) | 16 (48.5%) | 61 (50.8%) |
| Type of donor | ||||
| Living related | 157 (57.7%) | 24 (63.2%) | 16 (48.5%) | 72 (59.5%) |
| Living unrelated | 60 (22.1%) | 9 (23.7%) | 12 (36.4%) | 23 (19.0%) |
| Deceased | 55 (20.2%) | 5 (13.2%) | 5 (15.2%) | 26 (21.5%) |
| Pathological findings | ||||
| Coexisting acute rejection | 94 (34.6%) | 5 (13.2%) | 11 (33.3%) | 33 (27.3%) |
| Oxford classification | ||||
| Mesangial hypercellularity | ||||
| M0 | 142 (81.6%) | 23 (79.3%) | 18 (81.8%) | 56 (67.5%) |
| M1 | 32 (18.4%) | 6 (20.7%) | 4 (18.2%) | 27 (32.5%) |
| Endocapillary hypercellularity | ||||
| E0 | 130 (78.3%) | 16 (57.1%) | 16 (72.7%) | 49 (59.8%) |
| E1 | 36 (21.7%) | 12 (42.9%) | 6 (27.3%) | 33 (40.2%) |
| Segmental sclerosis | ||||
| S0 | 108 (61.7%) | 14 (48.3%) | 16 (72.7%) | 43 (51.2%) |
| S1 | 67 (38.3%) | 15 (51.7%) | 6 (27.3%) | 41 (48.8%) |
| Tubular atrophy/interstitial fibrosis | ||||
| T0 | 127 (72.6%) | 21 (72.4%) | 14 (63.6%) | 56 (67.5%) |
| T1 | 33 (18.9%) | 4 (13.8%) | 4 (18.2%) | 17 (20.5%) |
| T2 | 15 (8.6%) | 4 (13.8%) | 4 (18.2%) | 10 (12.0%) |
| Cellular/fibrocellular crescents | ||||
| C0 | 239 (87.9%) | 30 (78.9%) | 29 (87.9%) | 88 (72.7%) |
| C1 | 30 (11.0%) | 7 (18.4%) | 4 (12.1%) | 29 (24.0%) |
| C2 | 3 (1.1%) | 1 (2.6%) | 0 (0.0%) | 4 (3.3%) |
RAASB Renin-angiotensin-aldosterone system blockades, BB Beta blockers, CCB Calcium channel blockers, IgAN Immunoglobulin A nephropathy, eGFR Estimated glomerular filtration rate, BP Blood pressure, MAP Mean arterial pressure